Effect of dopaminergic agonists and antagonists on in vivo cyclic nucleotide content: relation of guanosine 3':5'- monophosphate (cGMP) changes in cerebellum to behavior.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D002531:Cerebellum / Q000187:drug effects / Q000378:metabolism*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006152:Cyclic GMP / Q000378:metabolism*; D004298:Dopamine / Q000502:physiology*; D018492:Dopamine Antagonists; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology; D006892:Hydroxydopamines / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D010243:Paralysis / Q000378:metabolism; D010891:Piribedil / Q000494:pharmacology; D051381:Rats
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D004873:Ergolines; D006892:Hydroxydopamines; D010891:Piribedil; D000242:Cyclic AMP; D006152:Cyclic GMP; D001058:Apomorphine; D004298:Dopamine